RTI Health Solutions, 300 Park Offices Dr., Research Triangle Park, NC 27709.
J Manag Care Spec Pharm. 2015 Dec;21(12):1184-93. doi: 10.18553/jmcp.2015.21.12.1184.
Among elderly patients, the management of type 2 diabetes mellitus (T2DM) is complicated by population heterogeneity and elderly-specific complexities. Few studies have been done to understand treatment intensification among elderly patients failing multiple oral antidiabetic drugs (OADs).
To examine the association between time to treatment intensification of T2DM and elderly-specific patient complexities.
In this observational, retrospective cohort study, elderly (aged ≥ 65 years) Medicare beneficiaries (n = 16,653) with inadequately controlled T2DM (hemoglobin A1c ≥ 8.0% despite 2 OADs) were included. Based on the consensus statement for diabetes care in elderly patients published by the American Diabetes Association and the American Geriatric Society, elderly-specific patient complexities were defined as the presence or absence of 5 geriatric syndromes: cognitive impairment; depression; falls and fall risk; polypharmacy; and urinary incontinence.
Overall, 48.7% of patients received intensified treatment during follow-up, with median time to intensification 18.5 months (95% CI = 17.7-19.3). Median time to treatment intensification was shorter for elderly patients with T2DM with polypharmacy (16.5 months) and falls and fall risk (12.7 months) versus those without polypharmacy (20.4 months) and no fall risk (18.6 months). Elderly patients with urinary incontinence had a longer median time to treatment intensification (18.6 months) versus those without urinary incontinence (14.6 months). The median time to treatment intensification did not significantly differ by the elderly-specific patient complexities that included cognitive impairment and depression. However, after adjusting for demographic, insurance, clinical characteristics, and health care utilization, we found that only polypharmacy was associated with time to treatment intensification (adjusted hazard ratio, 1.10; 95% CI = 1.04-1.15; P = 0.001).
Less than half of elderly patients with inadequately controlled T2DM received treatment intensification. Elderly-specific patient complexities were not associated with time to treatment intensification, emphasizing a positive effect of the integrated health care delivery model. Emerging health care delivery models that target integrated care may be crucial in providing appropriate treatment for elderly T2DM patients with complex conditions.
在老年患者中,2 型糖尿病(T2DM)的管理因人群异质性和老年患者特有的复杂性而变得复杂。很少有研究了解在多种口服降糖药(OAD)治疗失败的老年患者中强化治疗的情况。
研究 T2DM 治疗强化与老年患者特有复杂性之间的关系。
在这项观察性、回顾性队列研究中,纳入了年龄≥65 岁的 Medicare 受益人群(n=16653),这些患者的 T2DM 控制不佳(糖化血红蛋白≥8.0%,尽管使用了 2 种 OAD)。根据美国糖尿病协会和美国老年医学学会发布的老年糖尿病护理共识声明,老年患者特有的复杂性定义为是否存在 5 种老年综合征:认知障碍;抑郁;跌倒和跌倒风险;多种药物治疗;以及尿失禁。
总体而言,48.7%的患者在随访期间接受了强化治疗,强化治疗的中位时间为 18.5 个月(95%CI=17.7-19.3)。与无多种药物治疗(20.4 个月)和无跌倒风险(18.6 个月)的患者相比,患有多种药物治疗(16.5 个月)和跌倒和跌倒风险(12.7 个月)的 T2DM 老年患者的中位治疗强化时间更短。与无尿失禁的患者相比(14.6 个月),有尿失禁的老年患者的中位治疗强化时间更长(18.6 个月)。老年患者特有的复杂性包括认知障碍和抑郁,但治疗强化的中位时间并没有显著差异。然而,在调整了人口统计学、保险、临床特征和医疗保健利用情况后,我们发现只有多种药物治疗与治疗强化时间相关(调整后的危险比,1.10;95%CI=1.04-1.15;P=0.001)。
不到一半的 T2DM 控制不佳的老年患者接受了治疗强化。老年患者特有的复杂性与治疗强化时间无关,这强调了综合医疗服务提供模式的积极影响。针对综合医疗服务的新兴医疗服务模式可能对患有复杂疾病的老年 T2DM 患者提供适当的治疗至关重要。